North Star Asset Management Inc. Invests $9.83 Million in Prestige Consumer Healthcare Inc. $PBH

North Star Asset Management Inc. bought a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 208,000 shares of the company’s stock, valued at approximately $9,832,000. North Star Asset Management Inc. owned approximately 0.44% of Prestige Consumer Healthcare at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Public Employees Retirement System of Ohio purchased a new stake in Prestige Consumer Healthcare during the 2nd quarter worth about $1,554,000. Corient Private Wealth LP acquired a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth about $1,202,000. Bank of America Corp DE purchased a new position in shares of Prestige Consumer Healthcare in the 2nd quarter valued at about $26,277,000. Freestone Grove Partners LP purchased a new position in shares of Prestige Consumer Healthcare in the 2nd quarter valued at about $855,000. Finally, Man Group plc purchased a new position in shares of Prestige Consumer Healthcare in the 2nd quarter valued at about $5,628,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $51.27 on Friday. The stock’s 50-day moving average is $50.11 and its two-hundred day moving average is $54.64. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $71.07. The firm has a market cap of $2.43 billion, a price-to-earnings ratio of 14.36, a PEG ratio of 1.63 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. The firm had revenue of $265.71 million during the quarter, compared to analysts’ expectations of $253.02 million. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The business’s revenue was up 6.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Analysts predict that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current year.

Wall Street Analyst Weigh In

PBH has been the subject of several recent analyst reports. Oppenheimer cut Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, August 10th. Canaccord Genuity Group cut their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Finally, Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Hold” and an average price target of $70.75.

Prestige Consumer Healthcare News Summary

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Zacks projects earnings growth from $4.55 per share in FY2027 to $5.06 in FY2028 and $5.25 in FY2029, implying continued profit expansion for Prestige Consumer Healthcare.
• Neutral Sentiment: The firm estimates quarterly EPS of $1.06 for Q2 FY2027, $1.22 for Q3, and $1.30 for Q4. Its FY2027 forecast of $4.55 is broadly aligned with the current $4.56 consensus estimate.
• Neutral Sentiment: Zacks maintained a “Hold” rating on PBH, signaling limited conviction that the projected earnings growth currently warrants a more bullish stance. Prestige Consumer Healthcare analyst estimates
• Negative Sentiment: The update consists primarily of routine estimates for periods extending through FY2029, rather than a fresh earnings beat, guidance increase, or strategic announcement. That lack of a new positive catalyst may be weighing on the stock in the near term.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).